Research programme: invariant natural killer T-cells therapeutics - SalvaRx

Drug Profile

Research programme: invariant natural killer T-cells therapeutics - SalvaRx

Alternative Names: iNKT therapeutics - SalvaRx

Latest Information Update: 05 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ludwig Institute for Cancer Research; University of Oxford
  • Developer SalvaRx
  • Class Immunotherapies; Lipids
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Mar 2016 Preclinical trials in Cancer in United Kingdom (Parenteral)
  • 22 Mar 2016 SalvaRx plans a phase I/II trial for Cancer in United Kingdom
  • 11 Mar 2016 Ludwig Institute grants license to iOx Therapeutics for development of anti-cancer treatments based on invariant natural killer T-cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top